{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.1.1.', 'Regulatory and Ethical Considerations', '49', '10.1.2.', 'Informed Consent Process', '49', '10.1.3.', 'Data Protection', '50', '10.1.4.', 'Dissemination of Clinical Study Data', '50', '10.1.5.', 'Data Quality Assurance', '50', '10.1.6.', 'Source Documents', '51', '10.1.7.', 'Study and Site Closure', '51', '10.1.8.', 'Publication Policy', '52', '10.2.', 'Appendix 2: Clinical Laboratory Tests', '53', '10.3.', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow up, and Reporting', '55', '10.3.1.', 'Definition of AE', '55', '10.3.2.', 'Definition of SAE', '56', '10.3.3.', 'Adverse Events of Interest', '56', '10.3.4.', 'Recording and Follow Up of Adverse Events and Serious Adverse Events', '57', '10.3.5.', 'Reporting of SAEs', '59', '10.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', '60', '10.5.', 'Appendix 5: Genetics', '64', '10.6.', 'Appendix 6: Liver Safety - Actions and Follow-up Assessments', '65', '10.7.', 'Appendix 7: Visual Analog scale (VAS)', '68', '10.8.', 'Appendix 8: ACQ-5 Questionnaire', '69', '10.9.', 'Appendix 9: SNOT-22 Questionnaire', '72', '10.10.', 'Appendix 10: Prohibited and Restricted Medications and Treatments', '74', '10.11.', 'Appendix 11: Guidance to Address a Pandemic or Other Global Health', 'Emergencies and Potential Impact on the Clinical Study', '79', '10.12.', 'Appendix 12: Abbreviations', '80', '10.13.', 'Appendix 13: Protocol Amendment History', '83', '11.', 'REFERENCES', '91', '9', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'LIST OF TABLES', 'Table 1:', 'Investigational Product Formulation by Treatment Group', '30', 'Table 2:', 'Endoscopic Nasal Polyp Score', '39', 'Table 3:', 'Protocol-Required Safety Laboratory Assessments', '53', 'Table 4:', 'Liver Safety Laboratory Assessments', '54', 'Table 5:', 'Liver Chemistry Criteria Requiring Additional Monitoring with Possible', 'Interruption of Investigational Product', '65', 'Table 6:', 'Liver Chemistry Criteria Requiring Investigational Product Interruption and', 'Additional Monitoring', '66', 'Table 7:', 'Prohibited Medications and Treatments', '74', 'Table 8:', 'Restricted Medications Associated with an Increased Risk of Liver Injury', '75', 'Table 9:', 'Prohibited Medications Associated with CYP3A4 Induction or Inhibition', '76', 'Table 10: Prohibited Food and Herbal Supplements Associated with CYP3A4', 'Induction or Inhibition', '78', '10', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '1.', 'PROTOCOL SUMMARY', '1.1.', 'Synopsis', 'Protocol Title: A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to', 'evaluate the effect of GB001 in patients with chronic rhinosinusitis with or without nasal polyps', 'Short Title: GB001 in adult subjects with chronic rhinosinusitis', 'Rationale:', 'GB001 is a highly potent and selective oral prostaglandin D2 receptor (DP2) antagonist. DP2 is', 'expressed on a variety of cells implicated in the allergic process including eosinophils, basophils,', 'and epithelial cells (Kupczyk, 2017; Singh, 2017) as well as Group 2 innate lymphoid cells', '(ILC2) and T Helper cell type 2 (Th2) cells (Kato, 2019). GB001 is being developed as a once-', 'daily oral add-on maintenance treatment for patients with moderate to severe eosinophilic asthma', 'and related diseases.', 'The purpose of this Phase 2a study is to evaluate the efficacy, safety, pharmacokinetics (PK),', 'and pharmacodynamics (PD) of GB001 compared with placebo in patients with chronic', 'rhinosinusitis with or without bilateral nasal polyps (NP).', '11', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}